France· FR:68429472
QARZIBA 4,5 mg/ml, solution à diluer pour perfusion
A medicinal product containing dinutuximab bêta, registered in France by RECORDATI IRELAND.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- DINUTUXIMAB BÊTA
- Manufacturer
- RECORDATI IRELAND
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip1334009550332711 flacon(s) en verre de 20 mg
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Dinutuximab bêta in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsQarziba 4.5 mg/ml, concentraat voor oplossing voor infusieEUSA Pharma (Netherlands) B.V.
- FinlandQarzibaRecordati Netherlands B.V.
- BelgiumQarziba 4.5 mg/mlRecordati Netherlands
- United StatesUnituxinUnited Therapeutics Corporation
- CzechiaQARZIBARecordati Netherlands B.V., Schiphol-Rijk
- SpainQARZIBA 4,5 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONRecordati Netherlands B.V.
- CanadaUNITUXINUNITED THERAPEUTICS CORPORATION
- United KingdomQarziba 20mg/4.5ml concentrate for solution for infusion vialsRecordati UK Ltd
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Qarziba
- Liechtenstein · Qarziba
- Norway · Qarziba
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8c50664a-f664-4125-bebd-41be326703e8 GET /v1/drugs/8c50664a-f664-4125-bebd-41be326703e8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "68429472",
"date_amm": "2017-05-08",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/17/1191",
"substance": "DINUTUXIMAB BÊTA",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution à diluer pour perfusion",
"voies_administration": "intraveineuse",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about dinutuximab bêta.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.